Arrow image

10 Sep 2024

FDA Rule on Lab Developed Tests (LDTs)

2 | Understanding Compliance Tiers for Laboratory Developed Tests (LDTs)

WRITTEN BY

Divya Anantsri

SHARE THIS

Blog

In our previous blog in this series, we summarized the FDA’s plan to phase out the enforcement discretion policy for LDTs. To recap, the phase-out policy involves five stages spread across five years.

 

In this blog, we will elaborate on which rules apply to the various types of LDTs.

The types of compliance required are divided into Tiers 0-IV, as shown in the table below.

Tier 0 lists tests for which the compliance required by the final rule is already expected and enforced.

 

Thus, the stringency of compliance depends on the type of LDTs being manufactured.

If you are a new molecular LDT manufacturer, watch out for our next blog, which will elaborate on the specific processes that need to be set up and, importantly, how Strand can help.

 

Explore the rest of the blog series below:

Today’s Pick
from Blogs

30 Jun 2025

Strand’s Bioinformatics Expertise Enables Liquid Biopsy Assay Development for NSCLC with 70% Cost Reduction and 2–5% VAF Sensitivity

Suhasini Singh

Know More

26 Jun 2025

Strand’s qPCR Reporting Platform Accelerates Infectious Disease Diagnosis With ~2 min Turnaround Times

Sharon Christella

Know More

Your Next
Blog Recommendations

10 Nov 2023

Strand is heading to AMP2023!

Divya Anantsri

Know More

31 May 2024

Somatic Variations Series

1 | Precision Oncology: A Genetics Revolution in Cancer Management

Sanjna Banerjee

Know More

08 May 2024

Single-Cell RNA-Sequencing Data Curation Service & Data Showcase

Shrutee Jakhanwal

Know More

Let's
Talk

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Form
About image
Please fill out this form to
download the case study.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.